Low Dose Aspirin vs Placebo in Prevention of Recurrent Spontaneous Preterm Labour

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorUniversity of Health Sciences Lahore

About this trial

Preterm birth-defined as delivery before 37 weeks of gestation-is a leading cause of neonatal morbidity and mortality worldwide, particularly in resource-limited settings. Women with a history of spontaneous preterm birth face a significantly higher risk of experiencing premature labor in subsequent pregnancies. Impaired uteroplacental blood flow, inflammation, and abnormal clot formation are key contributing factors to spontaneous preterm delivery.

Low-dose aspirin is an affordable, widely available medication that exerts anti-inflammatory and antithrombotic effects by inhibiting platelet aggregation and prostaglandin synthesis. This study aims to evaluate whether low-dose aspirin (75 mg daily), initiated between 8 and 16 weeks of gestation, can effectively reduce the incidence of recurrent spontaneous preterm labor in pregnant women with a prior history of premature delivery compared to a placebo. Participants will be monitored throughout their pregnancy up to 36 weeks or delivery to evaluate gestational age at birth and labor outcomes.

Eligibility criteria

Qualifiers

Age > 18 years.

Singleton alive pregnancy.

History of spontaneous preterm birth (22 to 37 weeks of gestation).

Hemoglobin (Hb) > 10 g/dL.

Disqualifiers

Primigravida.

Multiple pregnancy.

Maternal age > 40 years.

Known history of allergy or hypersensitivity to aspirin.

Trial design

Treatments tested in this trial

  • Low-dose Aspirin
  • Placebo

Treatment groups

162 Participants
are divided into 2 treatment groups

Locations

This trial has no locations